Merino E, Caro E, Ramos J R, Boix V, Gimeno A, Rodríguez J C, Riera G, Más P, Sanchéz-Paya J, Reus S, Torrús D, Portilla J
José Manuel Ramos, Department of Internal Medicine, Hospital General Universitario de Alicante e Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Calle Pintor Baeza, 12; 03010 Alicante. Spain.
Rev Esp Quimioter. 2017 Aug;30(4):257-263. Epub 2017 Jun 8.
Bloodstream infections (BSIs) are associated with considerable morbidity and mortality among inpatients. The aim of this study was to evaluate the impact of a stewardship program on clinical and antimicrobial therapy-related outcomes in patients with bacteraemia.
Single-centre, before-and-after quasi-experimental study in adult inpatients. Over 1 January 2013 to 31 June 2013 all patients aged 18 years or older with a bacteraemia (interven-tion group, N=200) were compared to a historical cohort (1 Janu-ary 2012 to 31 December 2012) (control group, N=200).
Following blood culture results and adjusting for potential confounders, the stewardship program was associated with more changes to antibiotic regimens (adjusted odds ratio [ORa]: 4.6, 95% CI 2.9, 7.4), more adjustments to antimicrobial therapy (ORa: 2.4, 95% CI 1.5, 3.8), and better source control in the first five days (ORa 1.6, 95% CI: 1.0, 2.7). In the subgroup that initially received inappropriate empiric treatment (n=138), the intervention was associated with more antibiotic changes (OR: 3.9, 95% CI: 1.8, 8.5) and a better choice of definitive antimicrobial therapy (OR 2.3 95% CI: 1.2, 4.6). There were also more antibiotic changes in the subgroups with both Gram-negative (OR: 2.8, 95% CI: 1.6, 4.9; n=217) and Gram-positive (OR: 4.6, 95% CI: 1.8, 9.9; n=135) bacteraemia among those receiving the intervention, while the Gram-positive subgroup also received more appropriate definitive antimicrobial therapy (OR: 3.9, 95% CI: 1.8, 8.8).
The stewardship program improved treatment of patients with bacteraemia and appropriateness of therapy.
血流感染(BSIs)在住院患者中与相当高的发病率和死亡率相关。本研究的目的是评估一项管理计划对菌血症患者临床及抗菌治疗相关结局的影响。
对成年住院患者进行单中心前后对照准实验研究。将2013年1月1日至2013年6月31日期间所有年龄在18岁及以上的菌血症患者(干预组,N = 200)与一个历史队列(2012年1月1日至2012年12月31日)(对照组,N = 200)进行比较。
根据血培养结果并对潜在混杂因素进行调整后,管理计划与更多的抗生素方案更改(调整后的优势比[ORa]:4.6,95%可信区间2.9,7.4)、更多的抗菌治疗调整(ORa:2.4,95%可信区间1.5,3.8)以及头五天更好的源头控制(ORa 1.6,95%可信区间:1.0,2.7)相关。在最初接受不恰当经验性治疗的亚组(n = 138)中,干预与更多的抗生素更改(OR:3.9,95%可信区间:1.8,8.5)以及更恰当的确定性抗菌治疗选择(OR 2.3 95%可信区间:1.2,4.6)相关。在接受干预的革兰阴性菌血症(OR:2.8,95%可信区间:1.6,4.9;n = 217)和革兰阳性菌血症(OR:4.6,95%可信区间:1.8,9.9;n = 135)亚组中也有更多的抗生素更改,而革兰阳性菌血症亚组也接受了更恰当的确定性抗菌治疗(OR:3.9,95%可信区间:1.8,8.8)。
管理计划改善了菌血症患者的治疗及治疗的恰当性。